US 11,939,370 B2
Pan-ebola virus neutralizing human antibodies and methods of use therefor
James E. Crowe, Jr., Nashville, TN (US); Pavlo Gilchuk, Nashville, TN (US); and Alexander Bukreyev, Galveston, TX (US)
Assigned to VANDERBILT UNIVERSITY, Nashville, TN (US); and BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Appl. No. 17/259,263
Filed by VANDERBILT UNIVERSITY, Nashville, TN (US); and BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
PCT Filed Jul. 11, 2019, PCT No. PCT/US2019/041349
§ 371(c)(1), (2) Date Jan. 11, 2021,
PCT Pub. No. WO2020/014443, PCT Pub. Date Jan. 16, 2020.
Claims priority of provisional application 62/697,027, filed on Jul. 12, 2018.
Prior Publication US 2021/0403538 A1, Dec. 30, 2021
Int. Cl. C07K 16/10 (2006.01); A61K 39/00 (2006.01); A61P 31/14 (2006.01); G01N 33/569 (2006.01)
CPC C07K 16/10 (2013.01) [A61P 31/14 (2018.01); G01N 33/56983 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2469/10 (2013.01)] 15 Claims
 
1. A method of treating a subject infected with ebolavirus, or reducing the likelihood of infection of a subject at risk of contracting ebolavirus, comprising administering to said subject an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences selected from heavy chain CDR1-3 of SEQ ID NOS: 91, 92 and 93, and light chain CDR1-3 of SEQ ID NOS: 154, 155, and 156; heavy chain CDR1-3 of SEQ ID NOS: 118, 119 and 120, and light chain CDR1-3 of SEQ ID NOS: 181, 182, and 183; or heavy chain CDR1-3 of SEQ ID NOS: 127, 128 and 129, and light chain CDR1-3 of SEQ ID NOS: 190, 191, and 192.